Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)

Tomohiro Ishii; Makoto Anzo; Masanori Adachi; Kazumichi Onigata; Satoshi Kusuda; Keisuke Nagasaki; Shohei Harada; Reiko Horikawa; Masanori Minagawa; Kanshi Minamitani; Haruo Mizuno; Yuji Yamakami; Masaru Fukushi; Toshihiro Tajima

doi:10.1297/cpe.24.77

Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)

Tomohiro Ishii, Makoto Anzo, Masanori Adachi, Kazumichi Onigata, Satoshi Kusuda, Keisuke Nagasaki, Shohei Harada, Reiko Horikawa, Masanori Minagawa, Kanshi Minamitani, Haruo Mizuno, Yuji Yamakami, Masaru Fukushi, Toshihiro Tajima

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.

Original language	English
Pages (from-to)	77-105
Number of pages	29
Journal	Clinical Pediatric Endocrinology
Volume	24
Issue number	3
DOIs	https://doi.org/10.1297/cpe.24.77
Publication status	Published - 18-07-2015
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1297/cpe.24.77

Cite this

@article{fe0a15ee473d4dda81e0b31add925f8f,

title = "Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)",

abstract = "Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.",

author = "Tomohiro Ishii and Makoto Anzo and Masanori Adachi and Kazumichi Onigata and Satoshi Kusuda and Keisuke Nagasaki and Shohei Harada and Reiko Horikawa and Masanori Minagawa and Kanshi Minamitani and Haruo Mizuno and Yuji Yamakami and Masaru Fukushi and Toshihiro Tajima",

note = "Publisher Copyright: {\textcopyright} 2015, by The Japanese Society for Pediatric Endocrinology.",

year = "2015",

month = jul,

day = "18",

doi = "10.1297/cpe.24.77",

language = "English",

volume = "24",

pages = "77--105",

journal = "Clinical Pediatric Endocrinology",

issn = "0918-5739",

publisher = "Jeff Corporation Co. Ltd",

number = "3",

}

TY - JOUR

T1 - Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)

AU - Ishii, Tomohiro

AU - Anzo, Makoto

AU - Adachi, Masanori

AU - Onigata, Kazumichi

AU - Kusuda, Satoshi

AU - Nagasaki, Keisuke

AU - Harada, Shohei

AU - Horikawa, Reiko

AU - Minagawa, Masanori

AU - Minamitani, Kanshi

AU - Mizuno, Haruo

AU - Yamakami, Yuji

AU - Fukushi, Masaru

AU - Tajima, Toshihiro

PY - 2015/7/18

Y1 - 2015/7/18

N2 - Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.

AB - Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.

UR - http://www.scopus.com/inward/record.url?scp=84937858666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937858666&partnerID=8YFLogxK

U2 - 10.1297/cpe.24.77

DO - 10.1297/cpe.24.77

M3 - Article

AN - SCOPUS:84937858666

SN - 0918-5739

VL - 24

SP - 77

EP - 105

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

IS - 3

ER -

Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this